A Double-Blind Comparison of 0.25% and 0.05% Desoxymethasone, 0.1% Betamethasone Valerate and 1% Hydrocortisone Creams in the Treatment of Eczema

1987 ◽  
Vol 15 (3) ◽  
pp. 160-166 ◽  
Author(s):  
R. E. Ashton ◽  
M. Catterall ◽  
N. Morley ◽  
G. Fairris ◽  
D. N. Joseph
Keyword(s):  
Adverse Effects ◽  
Physical Properties ◽  
Effective Treatment ◽  
The Other ◽  
Betamethasone Valerate ◽  
Clinical Parameters ◽  
Double Blind ◽  
Parallel Group ◽  
Blind Comparison

The efficacy and acceptability of 0.25% and 0.05% desoxymethasone, 0.1% betamethasone valerate and 1% hydrocortisone creams were compared in patients with eczema. A double-blind parallel group multi-centre design was employed in which 96 patients were recruited by four centres. Patients used one cream for a 3-week period and follow-up assessment visits were made at weekly intervals. Efficacy variables were: erythema/redness, scaling, itching and extent of area affected. These variables were assessed by both the investigator and the patient. The 0.25% desoxymethasone was the most effective treatment, producing the greatest degree of improvement in all clinical parameters, hydrocortisone was the least effective and 0.05% desoxymethasone was of intermediate effectiveness. The 0.1% betamethasone produced similar results to 0.25% desoxymethasone for half the assessments; for the other half the results were similar to 0.05% desoxymethasone. No adverse effects were reported during the study. The results are discussed in terms of physical properties of the vehicles and corticosteroid potency.

Thylin - follow-up

1964 ◽  
Vol 2 (20) ◽  
pp. 80-80
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Chronic Arthritis ◽  
The Other ◽  
Double Blind ◽  
Previous Therapy ◽  
Blind Comparison

Since we discussed nifenazone (Thylin - West Pharmaceuticals) last April (Drug & Therap. Bull. 2, 26) Hart and Boardman1 have reported a trial of the drug, the first published in Britain. They substituted nifenazone 750–2000 mg daily for phenylbutazone, oxyphenbutazone or salicylates in 26 patients with painful chronic arthritis, mostly rheumatoid. In 18 of these the symptoms became worse; 7 showed some benefit, but less than with the previous therapy, and in one the improvement was comparable with that obtained from phenylbutazone 300 mg daily. Various side effects e.g. dyspepsia, nausea, mouth ulcers, rash occurred in 8 of the 26 patients. In 10 further patients with rheumatoid arthritis a double-blind comparison was made between nifenazone 500 mg three times daily and placebo tablets. Two patients withdrew from the trial; among the other 8, symptoms improved in one, but 7 noted no change. Objective criteria showed no significant improvement. The results of larger trials of the drug, to be published next November, will be awaited with interest.

Sulphadiazine/Trimethoprim Once Daily in Maxillary Sinusitis: A Randomized Double-Blind Comparison with Sulphamethoxazole/Trimethoprim B.I.D.

1981 ◽  
Vol 9 (6) ◽  
pp. 478-481 ◽  
Author(s):  
Pierre Federspil ◽  
Peter Bamberg
Keyword(s):  
Maxillary Sinusitis ◽  
Favourable Result ◽  
Double Blind Study ◽  
Double Blind ◽  
Once Daily ◽  
Days Of Therapy ◽  
Significant Difference ◽  
Blind Comparison ◽  
Cure Rates

In a randomized double-blind study fifty-four patients suffering from acute maxillary sinusitis were treated for 10 days with daily doses of sulphadiazine/trimethopim (1 g) and sulphamethoxazole/trimethoprim (1.92 g), respectively. The efficacy was evaluated clinically at two follow-up visits. X-ray investigations were performed at admission and after the therapy. Of thirty-nine patients finally evaluated, thirty-seven showed a favourable result. After 6–8 days of therapy there was significant difference in cure rates in favour of sulphadiazine/trimethoprim (p < 0.05) while the outcome as evaluated after treatment was similar for both drugs.

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.

1990 ◽  
Vol 8 (6) ◽  
pp. 1063-1069 ◽  
Author(s):  
J Bonneterre ◽  
B Chevallier ◽  
R Metz ◽  
P Fargeot ◽  
E Pujade-Lauraine ◽  
...  
Keyword(s):  
Group Analysis ◽  
Loading Dose ◽  
Breast Cancer Patients ◽  
Double Blind ◽  
Parallel Group ◽  
Blind Comparison ◽  
Prophylaxis Of Emesis ◽  
To Receive ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide. Ondansetron was given as an 8 mg loading dose (4 mg intravenously [IV] plus 4 mg orally) before chemotherapy followed by 8 mg every 8 hours orally for 3 to 5 days. Metoclopramide was given as an 80 mg loading dose (60 mg IV plus 20 mg orally) before chemotherapy followed by 20 mg every 8 hours orally for 3 to 5 days. A "period" interaction in the analysis of emetic response in the first 24 hours necessitated a parallel group analysis of first treatments only, 68 patients being assessable for this parameter. In the first 24 hours, complete or major control (zero to two emetic episodes) of emesis was achieved in 30 of 35 (86%) patients receiving ondansetron and in 14 of 33 (42%) patients receiving metoclopramide (P less than .001). Ondansetron was also more effective in reducing acute nausea. On days 2 to 3, the complete or major responses were significantly better with ondansetron (81% v 65%; P = .033), but there was no statistical difference in the control of nausea. There was a significant patient preference for ondansetron (63% v 26%; P = .001). Extrapyramidal reactions were observed in two metoclopramide treatments; both treatments were otherwise well tolerated. These results are consistent with serotonin (5-HT), being a significant neurotransmitter of cyclophosphamide/doxorubicin- or epirubicin/fluorouracil-induced emesis.

Iohexol and Meglumine Iothalamate in Shoulder Arthrography

1985 ◽  
Vol 26 (6) ◽  
pp. 757-760
Author(s):  
K. Tallroth ◽  
E. Vankka
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Contrast Medium ◽  
Consecutive Series ◽  
Contrast Injection ◽  
Double Blind ◽  
Shoulder Arthrography ◽  
Meglumine Iothalamate ◽  
Blind Comparison ◽  
Conventional Medium

The first clinical experience with the new contrast medium, iohexol, in shoulder arthrography is reported. A double-blind comparison of iohexol and meglumine iothalamate, a conventional medium in standard use for arthrography, was carried out in a consecutive series of 60 adult patients forming two groups of 30 subjects each. No difference in the radiographic quality was seen immediately after contrast injection but in exposures at 20 min iohexol gave a significantly better arthrographic quality. Practically no adverse effects occurred during the examinations. Although minor side effects were numerous in both groups during the two days following arthrography, they were somewhat more frequent in patients given iothalamate

scholarly journals The efficacy and safety of 'Antianxiety Granule' for anxiety disorder: A multicentre, randomized, double-blind, placebo-controlled, parallel-group trial

2019 ◽  
Author(s):  
Zhongwei Sha ◽  
Yiping Hou ◽  
Chunchun Xue ◽  
Ou Li ◽  
Zhimin Li ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Anxiety Disorders ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Parallel Group ◽  
Parallel Group Trial ◽  
Group Trial

Abstract Abstract Background: Anxiety disorders are the most prevalent class of lifetime disorders in China, and generalized anxiety disorder (GAD) is one of the most common but frequently overlooked anxiety disorders. Conventional pharmacological treatments for GAD have varying degrees of side effects, dependency, and/or withdrawal syndromes. Traditional Chinese Medicine (TCM) therapy is considered a valuable therapeutic option for anxiety disorders and a potentially effective technique to reduce the side effects associated with antipsychotic drugs. This trial aimed to evaluate the clinical efficacy and safety of Antianxiety Granule, a granular Chinese medicine compound, for GAD. Methods/Design: The current work is a multicentre, randomized, double-blind, placebo-controlled, parallel-group clinical trial with a 6-week treatment schedule. The study consists of three periods: a 1- to 7-day screening period, a 6-week primary treatment period, and a 1-week follow-up period. Follow-up assessments will be conducted one week after the last visit with a face-to-face interview or by telephone. The clinical efficacy of Antianxiety Granule for the treatment of GAD will be evaluated by examining the change in the Hamilton anxiety scale (HAMA) score, state-trait anxiety inventory (STAI) score, and TCM symptom scale in GAD patients who receive the daily TCM treatment. Moreover, an intention-to-treat (ITT) analysis will also be used in this randomized controlled trial (RCT). Discussion: Our study is a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the safety and efficacy of Antianxiety Granule for the treatment of GAD. The results of this trial will provide valuable clinical evidence for the treatment of GAD. Trial registration: The trial was registered with Chinese Clinical Trial Registry (http://www.chictr.org.cn/showproj.aspx?proj=27210) under the registration number ChiCTR1800016039 on 8 May 2018. The study was approved by the Ethics Committee of the Shanghai Municipal Hospital of Traditional Chinese Medicine (2017SHL-KY-14). Keywords: Generalized anxiety disorder (GAD), Traditional Chinese Medicine (TCM), RCT, Efficacy, Safety

Sign in / Sign up

Export Citation Format

Share Document